TickerGuard
Buy Day today: Neutral (51) Mixed market breadth · no major macro event
NVAX

Novavax Inc

Healthcare · Biotechnology

10.10$ +1.1% vs. previous close Closing price · As of: Sep 18, 2026

Ownership

Ownership Structure

Who owns Novavax Inc (NVAX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 86.4% of the shares are freely tradable; institutional investors hold 69.5%.

Institutional ownership ?Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings. 69.5%
Insiders ?Share of the stock held by the executives, founders and major shareholders of the company itself. 5.1%
Float ?Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders. 86.4%
Short % of float ?Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices. 29.8%
Shares Outstanding ?Total number of shares issued. Price times share count gives market cap. 165Mio.

Largest Shareholders

Institutions

Institutions NVAX
Name Stake (%) Shares Change (%) Date
Shah Capital Management 8.59 14,165,577 -4.6 06/30/2026
BlackRock Inc 7.79 12,844,319 -0.4 03/31/2026
State Street Corp 5.44 8,970,518 -5.8 03/31/2026
Vanguard Portfolio Management, LLC 4.34 7,151,625 +0.0 03/31/2026
Vanguard Capital Management, LLC 4.32 7,130,147 +0.0 03/31/2026
Sanofi 4.17 6,880,481 +0.0 06/30/2026
Bank of America Corp 4.02 6,637,213 -19.9 03/31/2026
D. E. Shaw & Co LP 3.43 5,650,905 -26.7 06/30/2026

Funds

Funds NVAX
Name Stake (%) Shares Change (%) Date
State Street® SPDR® S&P® Biotech ETF 4.80 7,923,303 -1.1 08/31/2026
Vanguard MStar Total Stk Mkt Idx Invest 3.15 5,197,170 +0.0 07/31/2026

Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.

Data as of: September 18, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?